Two preclinical programs reported strong efficacy in aggressive tumor models: Vivace Therapeutics’ VT‑3989, a TEAD inhibitor, suppressed growth of NF2‑deficient meningioma models; and M‑3554, an anti‑GD2 antibody‑drug conjugate with an exatecan payload, produced robust tumor regressions in soft tissue sarcoma models. VT‑3989 data support TEAD inhibition as a route to control tumors driven by Hippo pathway dysregulation; Vivace is advancing VT‑3989 into early clinical development for advanced solid tumors. M‑3554’s design (β‑glucuronide linker, exatecan payload) aims to reduce neuropathic pain typically associated with anti‑GD2 antibodies while retaining cytotoxicity in GD2‑expressing tumors. Both programs remain preclinical but underscore active, diversified oncology pipelines that combine targeted small molecules and next‑generation ADC designs. Watch for IND filings, biomarker development and early safety profiling that will determine translational viability.